Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Crysvita, also called Burosumab, is a medication designed for people with certain rare diseases that affect bone growth and strength. It works by targeting a specific protein in the body known as fibroblast growth factor 23 (FGF23). By blocking FGF23, Crysvita helps the body hold onto more phosphorus, which is important for keeping bones healthy. Doctors usually prescribe this medicine for conditions like X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). These conditions can make it difficult for bones to develop properly.
Fact Table | |
Formula | C6332H9792N1700O1992S42 |
License | US FDA, EMA |
Bioavailability | ~60% (subcutaneous) |
Legal status | Prescription only (Rx) |
Chemical Name | Burosumab |
Elimination half-life | 16-19 days |
Dosage (Strength) | 10 mg/mL, 20 mg/mL, 30 mg/mL solution for injection |
Pregnancy | Consult a doctor (No adequate data) |
Brands | Crysvita |
Protein binding | Not available (expected to be high) |
PubChem CID | 122878594 |
MedlinePlus | a618056 |
ChEBI | Not available |
ATC code | M05BX05 |
DrugBank | DB13977 |
KEGG | D11021 |
Routes of administration | Subcutaneous |
The frequency and dosage of Crysvita vary based on the condition being treated and the patient's weight. Typically, the starting dose for adults is administered once every four weeks, whereas children often have it once every two weeks. The exact dosage is calculated based on the person’s body weight.
Burosumab is the active ingredient in Crysvita.
Avoid using Crysvita if any of the following apply:
Common side effects of Crysvita injections include fever, cough, vomiting, headache, and pain in the extremities. Injection site reactions such as redness, swelling, or pain are also common. Some children might experience dental problems like tooth abscesses or cavities. These side effects are generally manageable and reflect the body's response to the medication.
More serious problems with Crysvita may include hypersensitivity reactions, which may develop as rashes or more severe skin reactions, and complications from elevated blood phosphate levels that might lead to conditions like nephrocalcinosis. If you experience any signs of severe allergic reactions, worsening skin conditions, or disturbances in phosphate levels, it's important to contact your healthcare provider immediately.